Clinical Trials Logo

Pulmonary Disease clinical trials

View clinical trials related to Pulmonary Disease.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05100160 Withdrawn - Pulmonary Disease Clinical Trials

Gabapentin for the Reduction of Opiate Use Following Pulmonary Resection (GROUP Trial)

Start date: September 15, 2021
Phase: Phase 3
Study type: Interventional

The aim of this study is to determine if the reduction in narcotic requirement following pulmonary resection with gabapentin is clinically significant when compared to the effect seen with placebo. We have defined clinically meaningful as a reduction by 30 Morphine equivalent doses (MED)

NCT ID: NCT04361461 Withdrawn - Pulmonary Disease Clinical Trials

Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)

Start date: April 30, 2020
Phase: Phase 3
Study type: Interventional

The Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV2) has been identified in Wuhan, China, which causes severe pulmonary complications and flu syndrome, which has spread rapidly to all continents. Approximately 25% of hospitalized patients require treatment in intensive care units and 10% require mechanical ventilation. The diagnosis is made by the molecular polymerase chain reaction test. However, diagnostic tests are limited. The clinical care of the patient with COVID-19 is similar to that of patients with severe infectious respiratory complications, consisting of support and oxygen supplementation. Several medications have been tested as remdesivir, a pro-drug nucleoside, which acts by inhibiting viral RNA transcription, although a recently published study has shown no benefit. China recently approved the use of favipiravir, an antiviral used for influenza, as an experimental therapy for COVID-19. Hydroxychloroquine is a drug with great potential treatment, as it can inhibit the pH-dependent steps of replication of various viruses, with a potent effect on SARS-CoV infection and spread. In this way, the present study will evaluate the safety and efficacy of the hydroxychloroquine in patients with symptomatic SARS-Cov2.

NCT ID: NCT04221100 Withdrawn - Pulmonary Disease Clinical Trials

xrAI - Improving Quality and Efficiency in Chest Radiograph Interpretation by Radiologists

Start date: March 2021
Phase: N/A
Study type: Interventional

xrAI (pronounced "X-ray") serves as a clinical assistance tool for trained clinical professionals who are interpreting chest radiographs. The tool is designed as a quality control and adjunct, limited, clinical decision support tool, and does not replace the role of clinical professionals. It highlights areas on chest radiographs for review by an interpreting clinician. The objective of this study is to utilize machine learning and artificial intelligence algorithms (xrAI) to improve the quality and efficiency in the interpretation of chest radiographs by radiologists. The hypothesis is that the addition of xrAI's analysis will reduce inter-observer variability in the interpretation of chest radiographs and increase participants' sensitivity, recall, and accuracy in pulmonary abnormality screening.

NCT ID: NCT02517671 Withdrawn - Clinical trials for Cardiovascular Disease

Impact of Enhanced External Counterpulsation (EECP) on VO2 MAX

Start date: January 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the effects of 35 EECP sessions on cardiopulmonary training performance in healthy volunteers. Data from this study will be used to generate sample size and power calculations for feasibility of future EECP studies. The results of this study could provide evidence that can help active duty and Department of Defense beneficiaries optimize physical conditioning, endurance and overall health.

NCT ID: NCT02282384 Withdrawn - Influenza Clinical Trials

An RCT of Oseltamivir in Outpatients With CPD: A Pilot Study.

AVT
Start date: October 2014
Phase: Phase 4
Study type: Interventional

The proposed pilot study will provide needed data to establish the feasibility of a conducting a large randomized controlled trial as to the effectiveness of the use of oseltamivir early in the course of influenza in outpatients with chronic pulmonary disease.

NCT ID: NCT00784329 Withdrawn - Lung Cancer Clinical Trials

Pilot Study To Evaluate Optical Frequency Domain Imaging For Diagnosis Of Central Airway Disease

Start date: March 2008
Phase: N/A
Study type: Interventional

To evaluate the potential of a new imaging device, termed Optical Frequency Domain Imaging (OFDI), in the early diagnosing of pulmonary malignancies in the central airways.